Salbutamol or mist in acute bronchiolitis

Area of Science:

• Pediatric Pulmonology
• Clinical Trials
• Pharmacology

Background:

• The efficacy of bronchodilators in treating bronchiolitis, a common infant respiratory infection, is debated.
• Current treatment guidelines often do not recommend bronchodilators for bronchiolitis.
• This study addresses the controversy by evaluating a specific bronchodilator, salbutamol.

Purpose of the Study:

• To evaluate the clinical response to nebulized salbutamol in infants diagnosed with acute bronchiolitis.
• To compare the effectiveness of salbutamol against placebo (saline) and supportive care (mist tent).
• To assess the safety and impact of salbutamol on respiratory parameters.

Main Methods:

• A double-blind, placebo-controlled trial involving 156 infants (7 weeks to 24 months) with bronchiolitis.
• Participants were randomized into three groups: nebulized salbutamol, nebulized saline, or mist tent.
• Respiratory scores, heart rate, oxygen saturation, and other clinical signs were monitored before and after treatment.

Main Results:

• The salbutamol group showed a significantly greater decrease in respiratory scores compared to saline and mist tent groups.
• Heart rate remained similar across all groups.
• A non-statistically significant decrease in oxygen saturation was observed in the salbutamol group.

Conclusions:

• Nebulized salbutamol demonstrated effectiveness in improving clinical symptoms of acute bronchiolitis.
• The study supports the safety of salbutamol for treating acute bronchiolitis in infants.
• Findings suggest a potential role for bronchodilators in managing bronchiolitis, challenging current controversies.